HeinemannL, KrinelkeL: Insulin infusion set: the Achilles heel of continuous glucose insulin infusion. J Diabetes Sci Technol, 2012; 6:954–964.
2.
HeinemannL, FlemmingGA, PetrieJR, et al.Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the study of Diabetes and the American Diabetes Association Technology Working Group. Diabetes Care, 2015; 38:716–722.
3.
KerrD, MortonJ, Whately-SmithC, et al.: Laboratory-based clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. J Diabetes Sci Technol, 2008; 2:450–455.
4.
PatelPJ, BenasiK, FerrariG, et al.: Randomized trial of infusion set function: steel versus Teflon. Diabetes Technol Ther, 2014; 16:15–19.
5.
PatteC, PleusS, WiegelC, et al.: Effect of infusion rate and indwelling time on tissue resistance pressure in small-volume subcutaneous infusion like in continuous subcutaneous insulin infusion. Diabetes Technol Ther, 2013; 15:289–294.
6.
GibneyM, XueZ, SwinneyM, et al.: Reduced silent occlusions with a novel catheter infusion set (BD FlowSmart): results from two open-label comparative studies. Diabetes Technol Ther, 2016; 18:136–143.
7.
BolickN, MorelD, GerthS, et al.: Reduction of silent occlusion occurrence during continuous subcutaneous insulin infusion [abstract]. Diabetes Technol Ther, 2015; 17(Suppl 1):A35.
8.
GibneyM, et al.: Continuous subcutaneous insulin infusion (CSII) sets—reduced flow interruptions with a novel investigational catheter infusion set [abstract]. American Diabetes Association Scientific Sessions, June2015.
